Form 4: TuHURA CEO Granted 3.4M Stock Options

TuHURA Biosciences CEO James A. Bianco was granted 3,414,891 stock options with an exercise price of $1.02, vesting over three years.

Summary

• James A. Bianco, the Chief Executive Officer and a Director of TuHURA Biosciences, Inc. (HURA), acquired 3,414,891 derivative securities in the form of stock options.
• The transaction date for this acquisition was December 12, 2025.
• Each option has an exercise price of $1.02.
• The options will vest in three equal annual installments, with one-third becoming exercisable on the first, second, and third anniversaries of December 12, 2025.
• The options have an expiration date of December 12, 2035.
• Following this transaction, James A. Bianco beneficially owns 3,414,891 derivative securities.

Sentiment

Score: 6

Explanation: The grant of stock options to the CEO indicates a commitment to long-term performance and aligns management incentives with shareholder interests, which is generally viewed positively. However, the filing itself does not contain operational or financial performance data to assess overall company sentiment.

Positives

• The grant of a significant number of stock options to the CEO aligns management's interests with long-term shareholder value creation.
• The vesting schedule over three years encourages sustained performance and commitment from the CEO.

Negatives

• The exercise of these options in the future could lead to dilution for existing shareholders.

Risks

• No specific risks are detailed in this Form 4 filing, as it primarily reports an insider transaction.

Future Outlook

The three-year vesting schedule for the stock options indicates a long-term incentive structure for the CEO, aligning future performance with equity ownership.

Industry Context

This Form 4 filing reports an individual insider transaction and does not provide information to analyze broader industry trends or competitor actions.

Stakeholder Impact

• Shareholders: Potential for future dilution if options are exercised, but also potential for increased shareholder value if the CEO's incentives lead to improved company performance.
• Management/Employees: The CEO receives a significant equity incentive, which can boost morale and commitment.

Next Steps

• The vesting of the stock options will occur in three annual installments, starting December 12, 2026.
• The options will remain exercisable until their expiration date of December 12, 2035.

Key Dates

Keywords

HURA, TuHURA Biosciences, stock options, insider transaction, CEO, director, Form 4, equity compensation